In the TP53-deficient breast cancer patient (DO5375) with 15 damaged genes detected (none of them known drivers), Vismodegib, an inhibitor of the Hedgehog signaling pathway, is proposed by PanDrugs as best therapeutic candidate driven by LRP2, a damaged gene that belongs to this pathway. The gene discussed is TP53; the disease is breast cancer.